Alan H. Bryce, MD, Director of the Genomic Oncology Clinic, Mayo Clinic, highlights the positive phase 3 data for rucaparib as a new standard of care for patients with mCRPC who previously received an androgen receptor pathway inhibitor but had not received chemotherapy in the castration-resistant setting.
TRITON3: Interim OS, Efficacy of Rucaparib Versus Chemo for mCRPC
By Alan H. Bryce, MD - Last Updated: February 24, 2023Post Tags:ASCO GU 2023-Prostate Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.